Cefoperazone/sulbactam (2:1 ratio) for the treatment of nosocomial infections caused by Acenetobacter baumannii or Pseudomonas aeruginosa in Thailand: a retrospective evaluation

摘要

Background: Over the past years, our hospitals have been suffering from sustained endemic due to A. baumannii. Multidrug-resistant A. baumannii has become increasingly common and restricts the empirical antibiotic for serious nosocomial infection (NI). Sulbactam has good in vitro activity against Acinetobacter spp. and many studies have shown cefoperazone/sulbactam (C/S) combination to be superior to that of cefoperazone alone against clinical isolates. Sulbactam is available in combination with cefoperazone in a fixed 1:1 or 2:1 ratio.